Product Code: 05-PHARM-PANEL-27
From £494.00
Deadline to order: 01/03/2027
Pharmacogenetic panel testing of markers for drug response and efficacy (Germline DNA).
A panel of clinically relevant variants in the ApoE, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, DPYD, fVl, HLA-B, NUDT15, SLCO1B1, TPMT, UGT1A1 and VKORC1 genes. If you undertake testing restricted to DYPD, or UGT1A1, then we also have a standalone EQA scheme for these pharmacogenetics markers.
CNV, MLPA, NGS, Panel testing, PCR based, Sanger sequencing
English, French, German, Italian, Spanish
DNA (in TE Buffer)
Yes
Jun-27
June - August 2027 (for exact dates see scheme instructions).
December 2027 - January 2028
You can complete purchase on our secure partner site.
The scheme is designed to assess the analytical process (genotyping), and reporting (biological and clinical interpretation of the test result) including the overall report layout, content and clerical accuracy.
To account for differing panel compositions, variants outside the stated scope of an individual laboratory’s panel will be excluded from their assessment.
More information, including the EMQN validation panel, is available on request and complete details will be provided in the scheme instructions.
Three mock clinical cases; 2 with matching samples and 1 virtual case will be provided. Approximately 3 µg DNA per sample is provided. Complete information will be available in the scheme instructions.
PLEASE NOTE: In previous years we have guaranteed at least one DPYD relevant clinical case scenario. Due to the provision of the DPYD and UGT1A1 EQA scheme, this will no longer be the case.
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form.
No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
added wishlist!
View Wishlist
View Wishlist
Express your interest in ''.
